Bailey, Clare

Carreño, Ester

Dick, Andrew D

Fotis, Konstantinos

Lee, Richard W J

Moutray, Tanya

Ross, Adam H

British Journal of Ophthalmology

AIM: To assess the efficacy of intravitreal ranibizumab for the treatment of new onset inflammatory choroidal neovascularisation (iCNV), including both uveitic and idiopathic CNVs.METHODS: Single-centre, open-label, non-randomised Phase IIb clinical trial. Patients fulfilling strict entry criteria of new onset iCNV were given monthly intravitreal ranibizumab injections for 3 months. Thereafter, re-treatment was based on evidence of persisting activity. All patients completed trial follow-up. Optical coherence tomography (OCT) and best-corrected visual acuity (BCVA) were performed at every visit. Fluorescein angiography was performed at baseline, months 4 and 12. Descriptive analysis and Wilcoxon non-parametric test were performed for analysis.RESULTS: 15 patients, 10 women with a mean age of 48.8 years (range 24-85 years) were included in the study. The mean number of injections was 4.33 (range 3-7). There was a statistically significant difference in the BCVA at month 4 (p=0.001) and at month 12 (p=0.001) compared with baseline. The mean gain in BCVA at month 4 compared with baseline was 20±15.36 letters (mean±SD), and at month 12 was 21±16.97 letters. There was a statistically significant difference in the mean central subfield thickness (CST) at baseline versus month 4 (p=0.003) and month 12 (p=0.001).CONCLUSION: Patients gained vision (mean of 21 letters at 12 months) and showed reduced CST. These results support the continued use of ranibizumab in the treatment of iCNV.TRIAL REGISTRATION NUMBER: 2008-007476-19, results.</p

Explore Bristol Research

Phase IIb clinical trial of ranibizumab for the treatment of uveitic and idiopathic choroidal neovascular membranes

Ester Carreño

Tanya Moutray

Konstantinos Fotis

Richard W J Lee

Andrew D Dick

Adam H Ross

Clare Bailey

Crossref

https://research-information.bris.ac.uk/files/106329510/Phase_IIb_clinical_trial_of_Ranibizumab_for_the_treatment_of_uveitic_and_idiopathic_choroidal_neovascular_membranes.pdf

Phase IIb clinical trial of ranibizumab for the treatment of uveitic and idiopathic choroidal neovascular membranes

Abstract

Similar works

Full text

Available Versions

Explore Bristol Research

Crossref